Compare Lowe`s Companies Inc (LOW) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Novo Nordisk A/S — how do they compare? Lowe`s Companies Inc trades at $203.98 (market cap $114.78B), while Novo Nordisk A/S trades at $49.32 (market cap $220.53B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| LOW | NVO | |
|---|---|---|
Market Cap | $114.78B | $220.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $71.70 |
52-Week Low | $204.76 | $35.29 |
Enterprise Value | $156.54B | $239.49B |
Dividend Yield | 2.44% | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
